Claudin 18.2-a FAST-moving target in gastric cancer?

被引：21
|
作者：
Athauda, A.
Chau, I. [1 ]
机构：
[1] Royal Marsden Hosp, Dept Med, London, England
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷 / 05期
关键词：
1ST-LINE TREATMENT; DOUBLE-BLIND; OPEN-LABEL; CAPECITABINE; ADENOCARCINOMA; EPIRUBICIN; ZOLBETUXIMAB; OXALIPLATIN; RILOTUMUMAB; CISPLATIN;
D O I：
10.1016/j.annonc.2021.02.021
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：584 / 586
页数：3
相关论文
共 50 条
  • [31] Target Therapy and Immunotherapy for Gastric Cancer-Recent Updates
    Karikalan, Barani
    Chakravarthi, Srikumar
    CURRENT CANCER THERAPY REVIEWS, 2022, 18 (03) : 202 - 208
  • [32] Claudin18.2 as a potential therapeutic target for primary ovarian mucinous carcinomas and metastatic ovarian mucinous carcinomas from upper gastrointestinal primary tumours
    Wang, Fujun
    Yang, Yao
    Du, Xiuzhen
    Zhu, Xiaoying
    Hu, Yanjiao
    Lu, Changyu
    Sui, Lei
    Zhao, Han
    Song, Kejuan
    Yao, Qin
    BMC CANCER, 2023, 23 (01)
  • [33] Claudin18.2 expression and clinicopathological features in cytology effusion specimens from gastric adenocarcinoma: A comparative study with tissue specimens
    Dai, Jiao
    Zheng, Heng
    Jin, Ju
    Cheng, Ye
    Xu, Haimiao
    CANCER CYTOPATHOLOGY, 2023, 131 (06) : 365 - 372
  • [34] Global Ring Study to Investigate the Comparability of Total Assay Performance of Commercial Claudin 18 Antibodies for Evaluation in Gastric Cancer
    Jasani, Bharat
    Taniere, Philippe
    Schildhaus, Hans-Ulrich
    Blighe, Kevin
    Parry, Suzanne
    Wilkinson, Dawn
    Atkey, Neil
    Clare-Antony, Scott
    McCabe, Clare
    Quinn, Christine
    Dodson, Andrew
    LABORATORY INVESTIGATION, 2024, 104 (01)
  • [35] Changing strategies for target therapy in gastric cancer
    Lee, Suk-young
    Oh, Sang Cheul
    WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (03) : 1179 - 1189
  • [36] Gastric cancer management: Kinases as a target therapy
    Farran, Batoul
    Mueller, Susanne
    Montenegro, Raquel C.
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2017, 44 (06) : 613 - 622
  • [37] Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer
    Micke, Patrick
    Mattsson, Johanna Sofia Margareta
    Edlund, Karolina
    Lohr, Miriam
    Jirstrom, Karin
    Berglund, Anders
    Botling, Johan
    Rahnenfuehrer, Joerg
    Marincevic, Millaray
    Ponten, Fredrik
    Ekman, Simon
    Hengstler, Jan
    Woell, Stefan
    Sahin, Ugur
    Tuereci, Oezlem
    INTERNATIONAL JOURNAL OF CANCER, 2014, 135 (09) : 2206 - 2214
  • [38] Claudin-4: A Potential Therapeutic Target in Chemotherapy-resistant Ovarian Cancer
    Yoshida, Hiroyuki
    Sumi, Toshiyuki
    Zhi, Xu
    Yasui, Tomoyo
    Honda, Ken-Ichi
    Ishiko, Osamu
    ANTICANCER RESEARCH, 2011, 31 (04) : 1271 - 1277
  • [39] Development and comparison of three 89Zr-labeled anti-CLDN18.2 antibodies to noninvasively evaluate CLDN18.2 expression in gastric cancer: a preclinical study
    Hu, Guilan
    Zhu, Wenjia
    Liu, Yu
    Wang, Yuan
    Zhang, Zheng
    Zhu, Shikun
    Duan, Wenwen
    Zhou, Peipei
    Fu, Chao
    Li, Fang
    Huo, Li
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (08) : 2634 - 2644
  • [40] Clinical Significance of KIAA1199 as a Novel Target for Gastric Cancer Drug Therapy
    Oneyama, Masataka
    Sakamoto, Naoya
    Oue, Naohide
    Kimura, Yayoi
    Hiroshima, Yukihiko
    Hashimoto, Itaru
    Hara, Kentaro
    Maezawa, Yukio
    Kano, Kazuki
    Aoyama, Toru
    Fujikawa, Hirohito
    Yamada, Takanobu
    Tamagawa, Hiroshi
    Yamamoto, Naoto
    Ogata, Takashi
    Cho, Haruhiko
    Ito, Hiroyuki
    Yukawa, Norio
    Shiozawa, Manabu
    Yoshikawa, Takaki
    Morinaga, Soichiro
    Rino, Yasushi
    Masuda, Munetaka
    Miyagi, Yohei
    Yasui, Wataru
    Oshima, Takashi
    ANTICANCER RESEARCH, 2019, 39 (12) : 6567 - 6573
12345